Positions

Associate Professor of Medicine in the School of Medicine

2024 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2023 School of Medicine

Education

M.D., Duke University 2006

2006 Duke University

Residency, Duke University, School of Medicine, GENERAL INTERNAL MEDICINE 2006 - 2009

2009 Duke University, School of Medicine

Fellowship, Duke University, School of Medicine, HEMATOLOGY / ONCOLOGY 2010 - 2013

2013 Duke University, School of Medicine

Clinical Trials

MB-CART2019.1 DLBCL (Diffuse Large B Cell Lymphoma)

A052101: Mantle Cell Lymphoma

Schrödi:Ph1 dose escalation of SGR-1505 as monotherapy in subject with mature B-cell malignancies

Publications, Grants & Awards

• Grants (32)
• Academics Articles (55)
• Conference Pages (35)
• Book Sections (15)

Showing 1 - 5 of 32

Long-Term Safety of Pirtobrutinib in Participants from Study LOXO-BTK-18001 with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

2025-2030Lilly USA, LLC

A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF SGR-1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL MALIGNANCIES

2024-2029Schrodinger, Inc.

INCB50465-801 Rollover (7008420

2023-2028Incyte Corporation

Viracta: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

2023-2028Viracta Therapeutics, Inc.

An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)

2023-2028Cellectar Biosciences, Inc.

DCI Centers, Cancer Types & Labs

Hematologic Malignancies and Cellular Therapy

Offices & Contact

2400 Pratt Street
Durham, NC
27710

Box 3961 Med Ctr
Durham, NC
27710